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OBJECTIVE: The majority of cases of hepatocellular carcinoma have been reported in individuals with cirrhosis
due to chronic viral hepatitis and alcoholism, but recently, the prevalence has become increasingly related to
nonalcoholic steatohepatitis around the world. The study aimed to evaluate the clinical and histophatological
characteristics of hepatocellular carcinoma in Brazilians’ patients with nonalcoholic steatohepatitis at the
present time.
METHODS: Members of the Brazilian Society of Hepatology were invited to complete a survey regarding patients
with hepatocellular carcinoma related to nonalcoholic steatohepatitis. Patients with a history of alcohol intake (420
g/day) and other liver diseases were excluded. Hepatocellular carcinoma diagnosis was performed by liver biopsy or
imaging methods according to the American Association for the Study of Liver Diseases’ 2011 guidelines.
RESULTS: The survey included 110 patients with a diagnosis of hepatocellular carcinoma and nonalcoholic fatty
liver disease from nine hepatology units in six Brazilian states (Bahia, Minas Gerais, Rio de Janeiro, Sa˜o Paulo,
Parana´ and Rio Grande do Sul). The mean age was 67±11 years old, and 65.5% were male. Obesity was
observed in 52.7% of the cases; diabetes, in 73.6%; dyslipidemia, in 41.0%; arterial hypertension, in 60%; and
metabolic syndrome, in 57.2%. Steatohepatitis without fibrosis was observed in 3.8% of cases; steatohepatitis
with fibrosis (grades 1-3), in 27%; and cirrhosis, in 61.5%. Histological diagnosis of hepatocellular carcinoma
was performed in 47.2% of the patients, with hepatocellular carcinoma without cirrhosis accounting for 7.7%.
In total, 58 patients with cirrhosis had their diagnosis by ultrasound confirmed by computed tomography or
magnetic resonance imaging. Of these, 55% had 1 nodule; 17%, 2 nodules; and 28%, X3 nodules.
CONCLUSIONS: Nonalcoholic steatohepatitis is a relevant risk factor associated with hepatocellular carcinoma in
patients with and without cirrhosis in Brazil. In this survey, hepatocellular carcinoma was observed in elevated
numbers of patients with steatohepatitis without cirrhosis.
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’ INTRODUCTION
Hepatocellular carcinoma (HCC) is considered the 5th most
common cancer in the world and it is responsible for 5% of all
malignant tumors in humans (1). It is also the most frequent
cause of all liver cancers, constituting 90% of cancers of the
liver globally and it has been estimated to be 3rd most
common cause of cancer-related death in humans (1-4).
The annual incidence of HCC among large series of
Brazilian cirrhotic patients was approximately 2.9%, with a
detection rate of 8.1% and a cumulative incidence rate over
five years of 14.3% (5).
The majority of cases of HCC have been reported to be
coincident with the presence of advanced chronic liver
disease associated with chronic hepatitis B virus (HBV)DOI: 10.6061/clinics/2016(05)07
Copyright & 2016 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
281
CLINICAL SCIENCE
or hepatitis C virus (HCV) infection or alcoholic
cirrhosis.
Cryptogenic cirrhosis (CC) is observed in 15-30% of
patients with advanced liver disease, and certain studies
have suggested that nonalcoholic fatty liver disease (NAFLD)
may be a risk factor for this condition (6,7). Moreover, the
growing prevalence of HCC around the world may be related
to NAFLD or nonalcoholic steatohepatitis (NASH).
In 2000, one of the first cases of HCC related to NASH was
reported in Brazil (8), and recently, two other Brazilian
studies on HCC and NAFLD were published (9,10). The
present survey aimed to evaluate the clinical and histo-
pathological characteristics of HCC in patients with
NAFLD/NASH throughout the country at the present time.
’ METHODS
Study design and population selection
Members of the SBH (Brazilian Society of Hepatology)
were invited to complete a survey regarding patients with
HCC related to NAFLD/NASH. The questionnaire included
questions about clinical and histological data from chart
review and also prospective analysis.
HCC was diagnosed according to the noninvasive
diagnostic criteria of the American Association for the Study
of Liver Diseases (AASLD), proposed in 2005 and updated in
2011 (11). Liver histology confirmation was performed in all
non-cirrhotic patients and in inconclusive cases by imaging
examination (computed tomography (CT) and/or magnetic
resonance imaging (MRI)).
The criteria for NAFLD diagnosis included the presence of
risk factors for NAFLD or metabolic syndrome, a history of
ethanol intake of o20 g/day, and exclusion of other liver
diseases (HBV and HCV infection, hemochromatosis, and
autoimmune hepatitis).
The Ethics Committee on Human Research at Faculdade de
Medicina da Bahia - Universidade Federal da Bahia (UFBA),
Brazil, approved the study. This study was conducted according
to the principles outlined in the Declaration of Helsinki (1964,
revised 2008).
Patient evaluation
Clinical evaluation included gender, age, anthropometric
measures, blood pressure levels, history of type 2 diabetes,
arterial hypertension, dyslipidemia, acute myocardial infarc-
tion, alcohol intake, smoking habits and use of medications
(including anti-diabetic, lipid-lowering, antihypertensive
and hepatotoxic drugs; glucocorticoids, estrogens, amiodar-
one, carbamazepine, and tamoxifen; and non-steroidal anti-
inflammatory drugs).
Laboratory tests included assessment of total cholesterol (TC),
high-density lipoprotein (HDL) cholesterol, low-density lipo-
protein (LDL) cholesterol, triglycerides (TG), glucose, insulin,
proteins, ferritin, transferrin saturation index, alanine amino-
transferase (ALT), aspartate aminotransferase (AST), gamma-
glutamyltransferase (GGT), alkaline phosphatase, hepatitis B
surface antigen (HBsAg), anti-HCV and autoantibodies (anti-
nuclear, anti-smooth muscle, and anti-mitochondria). Metabolic
syndrome was defined according to the National Cholesterol
Education Program Adult Treatment Panel III report (12).
Statistical analysis
Descriptive analyses were conducted using Statistical
Package for the Social Sciences software (SPSS Inc., Chicago,
IL, USA; Release 16.0.2, 2008). The analyzed data are expressed
as mean values, standard deviations, medians (Mdns) and
interquartile ranges (IQRs) according to the variables’
distribution.
’ RESULTS
The survey included 110 patients with diagnoses of HCC
and NAFLD from nine hepatology units in six Brazilian
states (Bahia, Minas Gerais, Rio de Janeiro, São Paulo, Paraná
and Rio Grande do Sul).
The mean age was 67±11 years old and 65.5% (72) were
male. Obesity was observed in 52.7% (58) of cases; diabetes,
in 73.6% (81); dyslipidemia, in 41.0% (45); arterial hyperten-
sion, in 60% (66); and metabolic syndrome, in 57.2% (63)
(Table 1). Histological diagnosis of HCC was performed in 52
(47.2%) patients; among these 52 patients, NASH with
cirrhosis was observed in 61.5%; NASH with fibrosis grades
1-3, in 27%; and NASH without fibrosis, in 3.8%. In 7.7% (4)
of cases, the histological diagnosis was only HCC (Table 2). A
total of 58 patients had a diagnosis of HCC by ultrasound
confirmed by CT or MRI. Of these, 55% had 1 nodule; 17%,
2 nodules; and 28%, X3 nodules. All of these cases were
associated with a cirrhotic liver (Table 3). Ascites was
observed in 19.0% of 93 patients with HCC; portal hyperten-
sion, in 39.7% of 86 patients, hypoalbuminemia (o3 g/dL), in
8.6% of 93 patients; and a prothrombin time below 70%, in
21.0% of 83 patients.
’ DISCUSSION
The present study suggests that HCC in Brazil is
associated with NASH and is also observed in non-cirrhotic
patients with and without fibrosis. Three previous studies
performed in this country reported cases of HCC in patients
with NASH (8-10). However, the present survey included a
large number of patients from several Brazilian centers and
regions.
NAFLD has been recognized as a frequent cause of HCC,
especially in Western countries. Environmental factors,
behavioral habits, metabolic features and inherited factors
have been implicated in the pathogenesis of HCC (13).
CC is observed in 15-30% of patients with advanced liver
disease and NASH has been associated with these cases (14).
Evidence that HCC is part of the natural history of
NAFLD, which includes steatosis, NASH, and cirrhosis,
comes from retrospective studies demonstrating that HCC is
related to NAFLD risk factors, case reports, prospective
studies that evaluated late complications in NAFLD patients
and studies in animal models (15-18).
Table 1 - Baseline characteristics of the patients with nonalcoholic
steatohepatitis and hepatocellular carcinoma (n=110).
n %
Gender
Male 72 65.5
Female 38 35.5
Elevated aminotransferases 85 56.2
Metabolic syndrome 63 57.2
Obesity 58 52.7
Diabetes 81 73.6
Hypertension 66 60
Dyslipidemia 45 41
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Certain aspects of the Brazilian survey described here
deserve discussion. In particular, the most frequent risk factors
found in patients with HCC and NASH were obesity and
diabetes, metabolic syndrome was observed in 57.2% of these
cases, and 72% of the cases presented fewer than three
nodules and fulfilled the Milan inclusion criteria for liver
transplantation. In this context, the major form of therapy for
HCC would be liver transplantation. However, ascites was
observed in 19.0% of 93 patients, and portal hypertension was
observed in 39.7% of 86 patients, with approximately 30%
presenting liver dysfunction. These findings suggest a late
diagnosis of HCC in this survey, in which case it is difficult to
administer curative treatment. Moreover, the main relevant
finding in this study was the elevated number of HCC cases
among NASH patients without cirrhosis. It was observed in
30.8% of the patients who underwent liver biopsy. Previously,
researchers in our group identified HCC cases without
cirrhosis in two published manuscripts (9,10). Several authors
have also recently described this intriguing phenomenon of
HCC in NASH patients without cirrhosis (17-19).
The physiopathology of the carcinogenesis of HCC in this
liver disease is not clear. However, metabolic factors such as
diabetes and obesity have been implicated.
In experimental studies with ob/ob rats (insulin-resistant
and obese), HCC has been observed in the absence of cirrhosis
(20). In these animals, the proliferation of hepatocytes was
increased compared with apoptosis, suggesting that this
imbalance could promote an increase in liver mass (21).
In humans, the physiopathology and molecular events that
lead to HCC are not well understood. However, certain
events have been observed: the proliferation of oval cells,
which are progenitors of hepatocytes implicated as the origin
of many liver tumors, including in patients with NAFLD
(22); increased production of reactive oxygen species and
oxidative injury (23,24); and mutations in regulatory genes,
including tumor suppressors such as p53 and phosphatase
tensin homolog (PTEN) (25).
The present study has certain limitations. For example, a
survey is a type of study in which the information is descriptive.
Therefore, it was not possible to follow up the patients; all of the
information collected came from the charts of the patients, and it
was not possible to obtain all of the clinical data. However, a
survey can yield relevant results and it can also suggest points
to be discussed. Based on the results of the present study, HCC
in patients with NASH with or without cirrhosis seems to be a
problem in Brazil, and this condition may become more
frequent in the next few years. The results also suggest the
relevance of the implementation of a surveillance protocol to
investigate HCC in Brazilian NASH patients.
This survey suggests that NASH is a relevant risk factor for
HCC in Brazil, whether associated with cirrhosis or not. In
particular, HCC was observed in an elevated number of
patients without cirrhosis. A surveillance protocol to inves-
tigate HCC in Brazilian NASH patients should be discussed.
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